By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ContraFect Corporation 

28 Wells Avenue, Third Floor

Yonkers  New York   10701  U.S.A.
Phone: 914-207-2300 Fax: n/a



Company News
FDA Grants Fast Track Designation To ContraFect (CFRXU)'s CF-301, The First Of Its Lysins, Currently In Development For The Treatment Of Staph Aureus Infections, Including MRSA 8/17/2015 11:19:53 AM
ContraFect (CFRXU) Announces Second Quarter 2015 Financial And Operating Results 8/13/2015 10:47:03 AM
ContraFect (CFRXU) Provides Update On CF-301 Phase 1 Trial 8/11/2015 11:05:30 AM
ContraFect (CFRXU) To Announce Second Quarter 2015 Results On August 13, 2015 8/7/2015 9:39:36 AM
ContraFect (CFRXU) Announces Issuance Of Key Patent Covering Novel Lysin Technology 7/20/2015 7:57:30 AM
ContraFect (CFRXU) Announces $20,000,000 Private Placement 6/12/2015 12:30:22 PM
ContraFect (CFRXU) Announces First Healthy Volunteer Dosed With CF-301 5/21/2015 10:01:50 AM
ContraFect (CFRXU) Adds Former Cubist Executive Steven C. Gilman, PhD, To Board Of Directors As Executive Chairman 5/20/2015 10:15:55 AM
ContraFect (CFRXU) Announces First Quarter 2015 Results 5/15/2015 10:47:46 AM
ContraFect (CFRXU) Announces Commencement Of Phase 1 Clinical Trial Of Cf-301 For Staph Bloodstream Infections, Including MRSA 4/29/2015 10:55:04 AM